Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05780320 · ClinicalTrials.gov registry record

A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery

A clinical trial, sponsored by Massachusetts General Hospital.

Completed
Registry status
242
Enrollment target

NCT05780320: Completed study, sponsored by Massachusetts General Hospital.

NCT05780320 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 242 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05780320 has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
242 participants
Enrollment target

Study Summary

Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery with an estimated incidence around 35%. It has been found to be an independent predictor of 30-day and 6-month mortality, stroke, renal failure, respiratory failure, and need for permanent pacemaker among others. Previous studies including meta-analyses demonstrate a protective benefit of prophylactic amiodarone to decrease the risk of POAF. However, this has not been widely adopted, and recent society guidelines only give prophylactic amiodarone a Class IIA recommendation, citing risk of amiodarone-related toxicity and hypotension as reasons for the Class IIA recommendation. A meta-analysis comparing cumulative doses of amiodarone found that moderate to higher doses of amiodarone have a marginally increased benefit in reducing the incidence of postoperative atrial fibrillation over lower doses; however, the study did not assess risk of complications stratified by cumulative doses, which has been previously described. Finally, a recent meta-analysis showed that a posterior pericardiotomy was highly effective at reducing postoperative atrial fibrillation. Consequently, the investigators' institution has adopted a pharmaco-surgical approach (prophylactic amiodarone and posterior pericardiotomy) in an effort to reduce postoperative atrial fibrillation after coronary artery bypass cardiac surgery for all patients who meet inclusion/exclusion criteria.

Primary Outcome

At least 1 minute duration detected by continuous telemetry or 12-lead electrocardiogram.

Interventions

  • OTHER Prophylactic amiodarone and posterior pericardiotomy

Trial Details

FieldValue
Enrollment Target 242 participants
Start Date 2022-09-19
Est. Completion 2025-03-15
Massachusetts General Hospital

2,032 total trials

What the finished NCT05780320 record still lists

NCT05780320 is an observational study that tracks outcomes without assigning an intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which Prophylactic amiodarone and posterior pericardiotomy is the first listed.

NCT05780320 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05780320 about?

NCT05780320 is a clinical study titled "A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery". Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery with an estimated incidence around 35%. It has been found to be an independent predictor of 30-day and 6-month mortality, stroke, renal failure, respiratory failure, and need for permanent pacemaker among oth...

What is the current status of trial NCT05780320?

This trial is currently completed. The enrollment target is 242 participants. The study started on 2022-09-19. Estimated completion is 2025-03-15.

What interventions are being tested in trial NCT05780320?

The interventions under investigation include: Prophylactic amiodarone and posterior pericardiotomy (OTHER).

Who is sponsoring clinical trial NCT05780320?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03556228 · 242 participants · Phase 1

    VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

  • NCT04260022 · 242 participants · Phase 1

    Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • NCT04459000 · 242 participants · NA

    Substance Use Treatment and Access to Resources (STARS) Project

  • NCT05644496 · 242 participants · Phase 4

    ZYNRELEF for Pain Management in Total Knee Arthroplasty

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05780320, the US trial registry maintained by the National Library of Medicine. NCT05780320 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.